Evidence map›Paper›PMID 40095056›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Innovative nanodelivery systems for targeted breast cancer therapy: overcoming drug delivery challenges and exploring future perspectives.

Dandan Su, Xiaolin Lai, Zhizhe Lin, Youfa Xu, Zhiqin Fu, Jianming Chen, Xin Wu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dandan Su *Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou, 350122, China.
Xiaolin Lai *Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou, 350122, China.
Zhizhe Lin *Shanghai Wei Er Lab, Shanghai, 201707, China.
Youfa XuShanghai Wei Er Lab, Shanghai, 201707, China.
Zhiqin FuShanghai Wei Er Lab, Shanghai, 201707, China.
Jianming ChenFujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou, 350122, China. chenjm0711@163.com.ORCID 0000-0001-8773-8494
Xin WuFujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou, 350122, China. wuxin007@126.com.ORCID 0000-0003-2875-355X

Funding

High-level Talents of Fujian University of Chinese Medicine X2019006-TalentsShanghai Enterprise Technology Center JJ-QYJS-01-22-0853Shanghai Oriental Talent Youth Project CYQN2023017
6 · The paper itself

Abstract

Cancer chemotherapy is often limited by insufficient drug targeting, which can cause severe adverse effects on healthy tissues. The advent of nanodelivery systems offers a potential solution to this issue. It intricately enhances drug accumulation in tumor regions, while optimizing drug solubility, ensuring colloidal stability, and promoting cellular uptake, significantly improving the precision and efficacy of treatment, opening a gentler yet more effective new path for cancer therapy. This article begins with the pathogenesis of breast cancer and extends to the current treatment methods and their shortcomings, exploring in-depth the targeting therapeutic effects of five innovative nanodelivery technologies used in the treatment of breast cancer in recent years. Finally, it discusses the potential opportunities and challenges that nanodelivery systems may face in future development.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsNanoparticle Drug Delivery SystemNanoparticlesAnimalsFemaleHumansAntineoplastic AgentsNanoparticle Drug Delivery SystemBreast cancerDrug deliveryNanomaterialsNanomedicineTumor targeting

Identifiers

PMID40095056

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.